

AN ORDINANCE **97307**

AUTHORIZING THE ACCEPTANCE OF AN AMOUNT NOT TO EXCEED \$15,390.00 IN CASH FROM GLAXOSMITHKLINE PHARMACEUTICALS FOR THE SAN ANTONIO METROPOLITAN HEALTH DISTRICT TO PARTICIPATE IN A FOLLOW-ON INFANRIX® VACCINE STUDY FOR THE PREVENTION OF DIPHTHERIA, TETANUS AND PERTUSSIS IN CHILDREN FROM JANUARY 31, 2003 THROUGH JANUARY 23, 2004; AUTHORIZING THE EXECUTION OF THE INVESTIGATOR AGREEMENT; ESTABLISHING THE PROJECT FUND; ADOPTING THE PROJECT BUDGET; AND AUTHORIZING PAYMENTS FOR CONTRACTUAL SERVICES.

* * * * *

WHEREAS, the San Antonio Metropolitan Health District (SAMHD) operates a program that provides immunizations to children for the prevention of diseases such as measles, rubella, mumps, diphtheria, tetanus, polio, haemophilus influenza b, pertussis, hepatitis A and varicella; and

WHEREAS, the success of this effort is dependent upon administering the proper vaccines on schedule to prevent disease outbreaks in the community; and

WHEREAS, GlaxoSmithKline Pharmaceuticals, a manufacturer of various medications, developed the INFANRIX® vaccine for infants 2 to 6 months of age, and has now developed the INFANRIX® booster for children 15 to 18 months of age for the prevention of diphtheria, tetanus and pertussis; and

WHEREAS, GlaxoSmithKline Pharmaceuticals has offered an agreement for an amount not to exceed \$15,390.00 in order for the SAMHD to participate in a follow-on clinical research study to evaluate the effectiveness of this vaccine booster and to determine the immune responses following co-administration of other routine childhood vaccines in young children for the period January 31, 2003 through January 23, 2004; and

WHEREAS, the City wishes to participate in this effort, which promotes the expanded use of an FDA approved drug known to prevent diphtheria, tetanus and pertussis in children; and

WHEREAS, it is now necessary to authorize the acceptance and execution of this agreement with GlaxoSmithKline Pharmaceuticals, establish the project fund, adopt the project budget and authorize payments for contractual services; **NOW THEREFORE:**

BE IT ORDAINED BY THE CITY COUNCIL OF THE CITY OF SAN ANTONIO:

SECTION 1. The City Manager, or her designee, is hereby authorized to accept and execute an Investigator Agreement with GlaxoSmithKline Pharmaceuticals, which will provide an amount not to exceed \$15,390.00 in order for the San Antonio Metropolitan Health District to participate in a follow-on vaccine study for the prevention of diphtheria, tetanus and pertussis in children during the period January 31, 2003 through January 23, 2004. A copy of this agreement is set out as Attachment II and incorporated herein for all purposes.

SECTION 2. Fund 26-012239 entitled "GSK Protocol 208355/125 Vaccine Study Project" is designated for use in accounting for this project.

SECTION 3. The sum of \$15,390.00 is hereby appropriated in the above-designated fund for the GSK Protocol 208355/125 Vaccine Study Project, and the budget attached hereto and incorporated herein as Attachment I is approved and adopted for entry on the City books.

SECTION 4. The one (1) personnel position set out in Attachment I and incorporated herein, is authorized for the activity shown thereon.

SECTION 5. The Director of Finance, may, subject to concurrence by the City Manager or the City Manager's designee, correct allocation to specific index codes and fund numbers as necessary to carry out the purpose of this ordinance.


SECTION 6. Should the agreement offered be in an amount other than that budgeted for, or should the agreement contain terms and conditions different than those currently existing, acceptance of the agreement, budget and corresponding personnel complement will be subject to subsequent City Council ordinance.

SECTION 7. This ordinance shall be effective on and after the tenth day after passage hereof.

PASSED AND APPROVED this 13th day of March, 2003.


M A Y O R
EDWARD D. GARZA

ATTEST: 
City Clerk

APPROVED AS TO FORM: 
City Attorney